Crossmark

Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry

Crossref DOI link: https://doi.org/10.1016/j.reumae.2020.04.008

Published Print: 2022-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Rosas, José

Senabre-Gallego, José Miguel

Santos-Soler, Gregorio

Antonio Bernal, José

Pons Bas, Ana
Funding

Funding for this research was provided by:

Asociación para la Investigación en Reumatología de la Marina Baixa
License Information

Text and Data Mining valid from 2022-03-01
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2020.04.008

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2020.04.011

Content Type: simple-article

Copyright: © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below